Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following is a summary of our net sales by category(1) (in millions):

	Three Months Ended				Nine Months Ended
	September 30, 2023		October 1, 2022		September 30, 2023		October 1, 2022
CSCA
Nutrition	$	130.7	$	124.4	$	435.4	$	376.7
Upper Respiratory	130.2		132.2		422.2		430.9
Digestive Health	117.1		119.6		368.0		363.3
Pain and Sleep-Aids	94.1		104.0		295.0		309.5
Healthy Lifestyle	79.4		73.8		220.1		208.7
Oral Care	76.5		83.6		237.8		230.6
Skin Care	47.6		48.9		150.7		138.4
Women's Health	10.2		12.4		34.6		32.6
Vitamins, Minerals, and Supplements ("VMS")	4.3		7.1		12.7		23.0
Other CSCA(2)	13.4		16.3		41.4		46.5
Total CSCA	$	703.5	$	722.3	$	2,217.9	$	2,160.2
CSCI
Skin Care	$	86.7	$	81.1	$	293.1	$	257.5
Upper Respiratory	78.2		69.2		227.9		194.5
Pain and Sleep-Aids	61.1		46.1		163.8		149.2
Healthy Lifestyle	52.4		47.6		179.4		165.6
VMS	46.1		46.4		135.4		138.2
Women's Health	28.5		28.7		89.5		65.7
Oral Care	24.8		21.7		75.5		71.2
Digestive Health	10.8		8.2		30.0		27.4
Other CSCI(3)	31.7		28.9		86.1		66.8
Total CSCI	420.3		377.9		1,280.7		1,136.1
Total net sales	$	1,123.8	$	1,100.2	$	3,498.7	$	3,296.3

(1) We updated our global reporting product categories as a result of our product portfolio reconfiguration. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows.

(2) Consists primarily of product sales and royalty income related to supply and distribution agreements and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of our rare diseases business and other miscellaneous or otherwise uncategorized product lines, none of which is greater

than 10% of the segment net sales.

We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended				Nine Months Ended
	September 30, 2023		October 1, 2022		September 30, 2023		October 1, 2022
U.S.	$	690.3	$	716.1	$	2,176.3	$	2,116.7
Europe(2)	399.8		365.1		1,232.6		1,098.8
All other countries(3)	33.7		19.0		89.8		80.8
Total net sales	$	1,123.8	$	1,100.2	$	3,498.7	$	3,296.3

(1) The net sales by geography are derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $11.9 million and $31.0 million for the three and nine months ended September 30, 2023, respectively, and $6.2 million and $20.1 million for the three and nine months ended October 1, 2022, respectively.

(3) Includes net sales generated primarily in Australia and Canada.

Schedule of Contract with Customer Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	September 30, 2023		December 31, 2022
Short-term contract assets	Prepaid expenses and other current assets	$	23.6	$	41.5